There are various angiotension-I converting enzyme inhibitors (ACEIs) have been investigated for palliating the hypertension. To produce ACE inhibitor peptides, 15 fragments of DNA sequences encoded well-known ACEI peptides from fish protein hydrolysates, GW, IW, KW, LF, MF, VW, VY, YL, GPL, GPM, IKW, VY, IRPVQ, IWHHT and IYPRY, were designed as a combinative DNA encoded a fusion ACEI polypeptide which could be hydrolyzed into individual ACEI peptides by chymotrypsin. The combinative DNA consisted of 234 nucleotides was cloned into the pET-23a(+) expression vector and then transformed into E. coli BL21(DE3) expression host. After 8 h induction by 0.1 mM isopropyl-β-D-thiogalactopyranoside, high activity of the recombinant fusion ACEI polypeptide was expressed. After sonication to disrupt the cell wall, the recombinant fusion ACEI polypeptide could be purified using Ni Sepharose™ 6 Fast Flow. The IC50 value of recombinant ACEI polypeptide is 11.82 μM. After chymotrypsin digestion, a 74-fold increase of ACEI activity (0.16 μM) was obtained, which was equivalent to 0.022 μM of captopril.The ACEI activity of the chymotrypsin hydrolysate increased about 74-fold activity after hydrolysis. It can be used in the health food for the prevention of high blood pressure, and even the development of drugs for medication in the future.